Regulatory Inspections
|
|
- Rafe Mitchell
- 7 years ago
- Views:
Transcription
1 How Bayer prepares for Pharmacovgilance Regulatory Inspections Dr Axel Röhrkasten Head Global GCP/PV System Audit Management Bayer Schering Pharma AG China Pharmacovigilance Forum 2009 September 21st, 2009, Beijing, China Global
2 Agenda Setting the scene Preparation of the Inspection Conduct of the Inspection Follow-up activities Recent trends Conclusion 2
3 y Health Authority PV Inspections Setting the scene A Pharmacovigilance Regulatory Inspection may be an extreme test of your capacity for delivery timely and proper responses on the company as a whole - Numerous document requests within several inspection days (to be collected from all around the world) 3
4 y Health Authority PV Inspections Setting the scene Types of PV Inspections - Routine To determine that the Marketing Authorization Holder (MAH) has personnel, systems and facilities in place to meet their regulatory obligations - Targeted Do not relate to specific concerns e.g. MAH has not previously been inspected Relate to specific concerns e.g. submission of poor quality or incomplete PSURs 4
5 y Health Authority PV Inspections Setting the scene Factors which may additionally trigger PV Inspections - Number of MAs held - MAH recently been involved in a merger or takeover process - Significant changes to PV System (e.g. new database system) - Number of products with known safety risks - Inspection history with specific non-compliances 5
6 y Health Authority PV Inspections Setting the scene Recent experience with PV Inspections at Bayer - FDA (Food and Drug Administration), the USA Health Authority - MHRA (Medicines and Healthcare products Regulatory Agency), the UK Medicines Agency - AFSSAPS (Agence Française de Sécurité Sanitaire des Produits de Santé), the French Medicines Agency - BfArM (Federal Institute for Drugs and Medical Devices)/ PEI (Paul-Ehrlich-Institute), li h t the German Medicines i Agency - Other country Health Authorities world-wide 6
7 y Health Authority PV Inspections Preparation Companies should have a global Quality System document covering Regulatory Inspections - At Bayer the following SOP covers all Pharmacovgilance & GCP Inspections (incl. audits conducted by Development Partners) 7
8 y Health Authority PV Inspections Preparation All quality processes (incl. Regulatory Inspections) should be managed in a centralized database - At Bayer one system exists to plan all Global activities and to collect, process, and report all quality data as part of a continual improvement process in order to improve regulatory compliance and efficiency - GREAT (TrackWise) is a web-based tracking software tool for electronically logging, managing, and trending quality issues and action items in accordance with cgxp standards 8
9 y Health Authority PV Inspections Preparation Notification of PV Inspection - Health Authority usually notifies sponsor several months in advance of inspection (However, on occasions, it may happen that inspections are conducted unannounced or announced only at short notice) - Recipient of inspection announcement immediately notifies relevant parties as defined in sponsor SOP i.e. Global at Bayer: CQA have an integral role in hosting and facilitating before, during and post regulatory inspection activities 9
10 y Health Authority PV Inspections Preparation IDRAC - collection of published Regulatory Affairs reference text (incl. translations) - e.g. Expert Reports 10
11 y Health Authority PV Inspections Preparation Frequently asked questions for Good Pharmacovigilance Practice - e.g. MHRA is regularly updating these Q&A news - e.g. MHRA Q&A news are published on dstandards/goodpharmacovigilancepractice/frequentlyaskedqu estions/index.htm 11
12 y Health Authority PV Inspections Preparation Inspection Metrics - e.g. MHRA is currently producing metrics reports every 6 months July to December 2006 January to June 2007 July to December 2007 January to June 2008 July to December e.g. MHRA metrics reports are published on dstandards/goodpharmacovigilancepractice/news/index.htm 12
13 y Health Authority PV Inspections Preparation Inspection Metrics (cont.) - e.g. Types of Critical Findings identified during Inspections (Source: MHRA Metrics Report July December 2008) A high proportion of critical findings were identified in the area of case processing during this period. 13
14 y Health Authority PV Inspections Preparation Good Pharmacovigilance Practice Guide e.g. Purple Guide - Compiled by the MHRA - Intended to complement currently available EU legislation and guidance - Provide practical advice to key stakeholders, in particular Marketing Authorization Holders, about achieving an appropriate system of Pharmacovigilance Contents: 1. EEA Qualified Person Responsible for Pharmacovigilance; 2. Management of Pharmacovigilance Data; 3. Spontaneous Case Processing; 4. Literature Searching; 5. Periodic Safety Update Reports; 6. Evaluation of Safety Data; 7. Risk Management Plans; 8. Reference Safety Information; 9. Quality Management System; 10. Interactions Between Pharmacovigilance and Other Functions; 11. Contracts and Agreements; 12. Safety Reporting for Clinical Trials; Annexes 14
15 y Health Authority PV Inspections Preparation Inspection Committee established - Represented by appropriate functions, main driver CQA - Tasks: Define Action Plan to prepare for inspection Ensure execution of actions Identify key sponsor contact to inspector Determine personnel to be present during inspection 15
16 y Health Authority PV Inspections Preparation Inspection Committee Action Plan Issues - Action any outstanding issues known for the system/facility to be inspected - Review files and organization documents for completeness and validity - Organize and update files and documents as appropriate - Review audit reports, if available 16
17 y Health Authority PV Inspections Preparation Inspection Committee Action Plan Issues (cont.) - Review any previous inspection documentation from the inspectorate, if relevant - Consult previous final summary reports of any relevant previous inspection to implement improvements, if applicable - Develop a pre-inspection audit plan, if required - Perform a pre-inspection audit, Mock inspection, if required - Other considerations 17
18 y Health Authority PV Inspections Preparation Briefing of sponsor staff - How to behave during an inspection Show professionalism during the inspection Friendly behavior in a spirit of partnership Interest in the inspector s s comments and recommendations Use the inspector s expertise for problem solving React quickly to requests 18
19 y Health Authority PV Inspections Preparation Briefing of sponsor staff (cont.) - How to behave during an inspection Reactions to questions Be clear of questions asked Answer known: quick and to the point Answer not known: admit it and show willingness to find out the answer Not sure. Ask for time to think about it and take the time you need No opinions, do not speculate, responses based on facts 19
20 y Health Authority PV Inspections Preparation Carefully yprepare p requested pre-inspection p PV documentation for Health Authority, e.g. - Description of Pharmacovigilance system - Procedural documents (e.g. SOPs/OMs) - Organograms - CVs, job descriptions - Contracts and agreements - Line listings - PSURs for selected products - etc. 20
21 y Health Authority PV Inspections Preparation Logistics - Inform all relevant sponsor staff of inspections - Inform all relevant external parties of inspection - Ensure equipment requested by inspector is available - Ensure translation of documents, if required for foreign inspections - Arrange for translator to be present during inspection - Arrange practicalities as necessary (travel, communication lines, etc.) - Make suitable catering arrangements 21
22 y Health Authority PV Inspections Conduct Inspectors Scribe Runner Inspector Inspector in same room Individuals in backroom : as defined; decision as to which individuals and which documents are made available to inspector(s) 22
23 y Health Authority PV Inspections Conduct Internal Procedures - Scribe to map relevant discussions - Channeling any request via Scribe Runner to gather requested information - Backroom personnel to support interviewees and to prepare requested documentation: Copies are marked and stamped confidential to distinguish from originals i and to ensure confidentiality A duplicate set is made for the company A document log is maintained 23
24 y Health Authority PV Inspections Conduct 24
25 y Health Authority PV Inspections Conduct Interviews - Generally very detailed and probing - Large numbers of staff may be interviewed, even in groups - Non PV staff interviewed (e.g. Sales Reps, Webmasters, Security, Medical Information, Regulatory Affairs, Product Quality) - Focus on interfaces (e.g. reconciliation of data) - Course of interview may trigger number of requests for documentation 25
26 y Health Authority PV Inspections Conduct Potential PV Inspection Agenda Day 1-4 Opening Meeting Roles and responsibilities of the EU/EEA Qualified Person Interactions with Medical Information Processing and follow-up of spontaneous ADR reports Interactions with Product Quality Interactions with Regulatory Affairs Clinical Trial Safety Monitoring and PASS studies PSUR and ASR production Proposed time Staff to be interviewed 26
27 y Health Authority PV Inspections Conduct Potential PV Inspection Agenda (cont.) Day 1-4 Safety signal detection and ongoing product safety review Processing and follow-up of literature t searches Safety database: validation, change control, back-up, security, maintenance & disaster recovery Management of PV SOPs and policies/procedures and PV training QA audits of the PV system Closing meeting Proposed time Staff to be interviewed 27
28 y Health Authority PV Inspections Conduct Daily Wrap-up p Meetings - With inspector(s), if possible: Clarification of outstanding issues/pending requests of documentation Agreement on agenda for next day (if different from original plan) - Internally: Determination of actions and definition of responsible persons 28
29 y Health Authority PV Inspections Conduct Closing Meeting - Inspectors will provide general overview of the outcome, address specific findings, and might offer advice - Sponsor has the chance to clarify inconsistencies and provide appropriate response to all observations - Sponsor should make no attempts to whitewash known deficiencies or weak points - Timeframe for written response defined d by Inspectors - Inspectors may take documentation with them 29
30 y Health Authority PV Inspections Conduct Findings and Observations - Generally 3 categories, i.e. critical, major and other/minor - A critical finding may trigger an early re-inspection (e.g. MHRA - within 12 months) Inspection Report - Inspectors usually issue inspection report several weeks/months after inspection - Sponsor is expected to reply on inspection report to Health Authority in time 30
31 y Health Authority PV Inspections Follow-up Findings and Observations Format of response, e.g. MHRA - Response Corrective Action Preventative Action dstandards/goodclinicalpractice/index.htm 31
32 y Health Authority PV Inspections Follow-up Corrective and Preventive Action (CAPA) Process - Inspection Committee at Bayer agrees on appropriate CAPA activities and prepares response to Health Authority - Responses must be realistic in both content and timelines - CAPA Compliance Manager monitors status via GREAT and escalates agreed actions which are not progressing on schedule - Database support assures systematic measurement of CAPA effectiveness - Trend reports across several PV inspections and internal PV audits support continuous process improvement 32
33 y Health Authority PV Inspections Recent trends MHRA - MHRA launched their new risk-based inspection program in April It is now considered that the scope, frequency and depth of inspections should be dependent on how organizations take responsibility for their own compliance with the regulations - Companies to complete self assessment questionnaire once a year (not mandatory, but otherwise automatic high risk ranking) - Individual algorithms for each of the GxPs (GLP, GCP, GDP, GMP & GPvP) - Completed compliance reports were expected to be submitted to MHRA by 30 June 2009 (later extended to 01 September 2009) 33
34 y Health Authority PV Inspections Recent trends MHRA (cont.) - Companies will not be given the precise risk score, only a relative ranking of high, medium or low risk - Inspections are prioritized for companies within the high-risk category - For control purposes, a small number of organizations from the other categories will also be randomly selected - The inspection process itself will be largely l indistinguishable i from that followed in recent years dstandards/goodpharmacovigilancepractice/riskbasedinspectio ns/index.htm 34
35 y Health Authority PV Inspections Recent trends Harmonizing EU Inspection Processes - First meeting of the EU Pharmacovigilance Inspectors Working party was held in July Joint inspections are occurring with other Member State Inspectorates in the EU and in third countries EMEA, FDA launch joint GCP inspection initiative - A bilateral initiative aimed at maximizing resources for Good Clinical i l Practice (GCP) inspections was recently announced by the European Medicines Agency (EMEA) and the US Food and Drug Administration (FDA) and was said to start with an 18- month pilot phase on September 1st, 2009 (incl. informationsharing and collaborative GCP inspections) 35
36 y Health Authority PV Inspections Conclusion and always remember that the goals of the company and of the inspectors are the same to protect public health 36
37 37
38
The EU Clinical Trial Regulation A regulator s perspective
5 The EU Clinical Trial A regulator s perspective Author Martyn Ward, Group Manager, Licensing, Medicines and Healthcare products Regulatory Agency (MHRA), UK. Keywords Clinical Trial Directive (the Directive);
More informationGMP Training Course Inspections from an industry perspective. 20-21 October 2009 Fiona Routley MHRA Inspector (UK)
GMP Training Course Inspections from an industry perspective 20-21 October 2009 Fiona Routley MHRA Inspector (UK) Objective To provide an insight into how arranged inspections are prepared and managed.
More informationSerious Breaches. Ian Gravenor. Senior Clinical Project Manager Novo Nordisk Ltd
Serious Breaches Ian Gravenor Senior Clinical Project Manager Novo Nordisk Ltd Serious Breaches of GCP or the Trial Protocol Agenda Why report? The legislation MHRA Guidance document Timelines Actions
More informationGuidance notes. for Patient Safety and Pharmacovigilance in Patient Support Programmes
Guidance notes for Patient Safety and Pharmacovigilance in Patient Support Programmes 9 May 2011 Approval Status Authors The ABPI Pharmacovigilance Expert Network Change History N/A Approval Date 9 May
More informationMedDRA in pharmacovigilance industry perspective
MedDRA in pharmacovigilance industry SFDA ICH MedDRA Workshop, Beijing, 13 14 May 2011 Christina Winter, MD, FFPM Medical director GlaxoSmithKline R&D / ICH MedDRA Management Board 2011 ICH International
More informationPROCEDURE FOR PREPARING GCP INSPECTIONS REQUESTED BY THE EMEA. GCP Inspectors Working Group
European Medicines Agency Inspections London, 20 September 2007 EMEA/INS/GCP/197228/2005 Procedure no.: INS/GCP/2 PROCEDURE FOR PREPARING GCP INSPECTIONS REQUESTED BY THE EMEA GCP Inspectors Working Group
More informationThe Application and Inspection Process What to Expect
82 GUIDANCE ON WHOLESALE DISTRIBUTION PRACTICE AND BROKERING Qualification of Customers and Suppliers 112 Qualification of suppliers 113 Compliance with GDP 113 Routine re-qualification 114 Due diligence
More informationTrackWise - Quality Management System
TrackWise - Quality Management System Focus area: Electronic Management of CAPA Systems in the Regulated Industry May 11, 2007 Yaniv Vardi VP, Operations Sparta Systems Europe, Ltd. Agenda Sparta Systems
More informationPHV- 4 version 1 ELECTRONIC ADVERSE DRUG REACTION REPORTING
PHV- 4 version 1 ELECTRONIC ADVERSE DRUG REACTION REPORTING This guideline supersedes guideline PHV 4 as of September 16 2008. 1. Introduction and general provisions 1.1 Purpose of the guideline The guideline
More informationBEMA Benchmarking European Medicines Agencies. linking competence to achieve excellence
BEMA Benchmarking European Medicines Agencies linking competence to achieve excellence EU/EEA Medicines Network linking loose pearls to a chain EU/EEA Medicines Network linking loose pearls to a chain
More informationSTANDARD OPERATING PROCEDURE FOR RESEARCH. 2. Notification of Serious Breaches of Good Clinical Practice or Study Protocol
Basildon and Thurrock University Hospitals NHS FT Research & Development APPROVED STANDARD OPERATING PROCEDURE FOR RESEARCH 2. Notification of Serious Breaches of Good Clinical Practice or Study Protocol
More informationClinical trials in developing countries submitted to EMEA for regulatory purposes
Clinical trials in developing countries submitted to EMEA for regulatory purposes Rome, UNICRI/AIFA December 2008 Hans-Georg Eichler Agenda Challenges EU regulatory requirements for clinical trials Facts
More informationThe Clinical Trials Directive in the EU: Present and Future Elisabethann Wright, Partner Maurits Lugard, Partner. May 2010
The Clinical Trials Directive in the EU: Present and Future Elisabethann Wright, Partner Maurits Lugard, Partner May 2010 Background (1) The Clinical Trials Directive 2001/20/EC The intention of this Directive
More informationPharmacovigilance System Master File (PSMF), QPPV and audits
Federal Agency for Medicines and Health Products (FAMHP) Pharmacovigilance System Master File (PSMF), QPPV and audits Matthijs Nele, PhV Inspector, DG Inspection BRAS - FAMHP/NM/ 1 Content Introduction
More informationEMA Clinical Laboratory Guidance - Key points and Clarifications PAUL STEWART
EMA Clinical Laboratory Guidance - Key points and Clarifications PAUL STEWART Framework Labs generate data that are used to make decisions on the safety and efficacy of medicinal products; consequently,
More informationEU Clinical Trials Regulation Regulation EU 536/2014
EU Clinical Trials Regulation Regulation EU 536/2014 María Jesús Zafra Director, QA & Compliance Table of contents 1 2 3 4 Introduction Timelines and main changes Highlights 5 Impact on company processes
More informationAgence fédérale des médicaments et des produits de santé
Agence fédérale des médicaments et des produits de santé From Risk Management Plan to Risk Minimization Activities New Royal Decree: Status and General Explanation Role of the Pharmacovigilance Department
More informationStakeholder Meeting, 7 th June 2013 An inspector s perspective considerations for patient support and reimbursement programmes
Stakeholder Meeting, 7 th June 2013 An inspector s perspective considerations for patient support and reimbursement programmes Dr Anya Sookoo, Expert Inspector, Inspections, Enforcement & Standards Division,
More informationNew Investigator Collaborations and Interactions: Regulatory
Your Health and Safety... Our priority Votre santé et votre Securité notre priorité New Investigator Collaborations and Interactions: Regulatory NCIC Clinical Trials Group New Investigator Clinical Trials
More informationAPEC Preliminary Workshop: Review of Drug
APEC Preliminary Workshop: Review of Drug Development in Clinical Trials Session 1.4 -Clinical Trial Environment United States (FDA) and European Union (EMEA) Susan D Amico Vice President and Global Head
More information1 www.imarcresearch.com
Risk Management in Clinical Research: PROCESS DEVELOPMENT & APPLICATION Introduction Recently, two key pieces of guidance were released from Food and Drug Administration (FDA) and European Medicines Agency
More informationQuality Thinking in other Industries. Dominic Parry Inspired Pharma Training. WEB www.inspiredpharma.com GMP BLOG inspiredpharmablog.
Quality Thinking in other Industries Dominic Parry Inspired Pharma Training WEB www.inspiredpharma.com GMP BLOG inspiredpharmablog.com Welcome The traditional focus on quality Quality in the eyes of GMP
More informationRisk Management in the Pharmaceutical Industry. Elena Apetri, Global Medical Safety Surveillance Schering AG
Risk Management in the Pharmaceutical Industry Elena Apetri, Global Medical Safety Surveillance Schering AG Topics Environment Safety Risk Management Guidance Safety RM Systems Signal detection and evaluation
More informationPreparing for Unannounced Inspections from Notified Bodies
Preparing for Unannounced Inspections from Notified Bodies Europe has introduced further measures for unannounced audits of manufacturers by notified bodies. With this in mind, James Pink, VP Europe-Health
More informationCreating excellence in professional standards and practices to enable Healthcare market researchers to become highly valued business partners
Creating excellence in professional standards and practices to enable Healthcare market researchers to become highly valued business partners EphMRA Vision EMA Workshop on Patient Support Programmes and
More informationMedical Information and Pharmacovigilance through acquisition. Lisa Hughes Medical Affairs Manager Actavis UK Ltd
Medical Information and Pharmacovigilance through acquisition Lisa Hughes Medical Affairs Manager Actavis UK Ltd Disclaimer The views and opinions expressed in the following presentation are those of the
More informationQUALITY MANAGEMENT POLICY & PROCEDURES
QUALITY MANAGEMENT POLICY & PROCEDURES Policy Statement Cotleigh Engineering Co. Limited specialises in the recruitment of engineering & technical personnel in the oil & energy, rail, civil engineering,
More informationThe Concept of Quality in Clinical Research. Dorota Śwituła Senior Clinical Quality Assurance Advisor
The Concept of Quality in Clinical Research Dorota Śwituła Senior Clinical Quality Assurance Advisor 1 Agenda What is quality? How we define quality in clinical research? The standard components of a Quality
More informationCHAPTER 5 - SAFETY ASSESSMENTS, LOG OF DEFICIENCIES AND CORRECTIVE ACTION PLANS
CHAPTER 5 - SAFETY ASSESSMENTS, LOG OF DEFICIENCIES AND CORRECTIVE ACTION PLANS A. INTRODUCTION... 1 B. CHAPTER-SPECIFIC ROLES AND RESPONSIBILITIES... 1 C. SAFETY PROGRAM ASSESSMENT PROCESS... 3 D. FACILITY-MAINTAINED
More informationBiotech Concerto #3. European Clinical Trial Environment
Biotech Concerto #3 European Clinical Trial Environment December 2008 Index EU Directive EU Approval System European Authority: EMEA The Guidance Documents Route Map Challenges EMEA Organization Chart
More informationApproaching The Response To Audit Observations
Approaching The Response To Audit Observations By Troy Fugate Understanding your systems and taking responsible and appropriate actions are at the core of beneficial audit responses. Systemically applying
More informationComputerised Systems. Seeing the Wood from the Trees
Computerised Systems Seeing the Wood from the Trees Scope WHAT IS A COMPUTERISED SYSTEM? WHY DO WE NEED VALIDATED SYSTEMS? WHAT NEEDS VALIDATING? HOW DO WE PERFORM CSV? WHO DOES WHAT? IT S VALIDATED -
More informationApproaching the Response to Audit Observations
Introduction Approaching the Response to Audit Observations One of the first things consistently drilled into my collective memory was the statement that we should always be prepared for an audit. It was
More informationIdentification of Medicinal Products (IDMP) What is necessary in order to be compliant in 2016 and beyond?
Identification of Medicinal Products (IDMP) What is necessary in order to be compliant in 2016 and beyond? February 2015 Audit. Tax. Consulting. Corporate Finance. New ISO standards have been developed
More informationTitle:: Effective GMP AUDITS for APIs and Formulation Pharma Companies By G.Sundar-Director/Consultant PharmQA Compliance solutions
WELCOME Title:: Effective GMP AUDITS for APIs and Formulation Pharma Companies By G.Sundar-Director/Consultant PharmQA Compliance solutions Contents: Introduction GMP Audit GMP Audit plan GMP Auditing
More informationRisk Management Plan for Drug Establishments
Republic of the Philippines Department of Health FOOD AND DRUG ADMINISTRATION Risk Management Plan for Drug Establishments Center for Drug Regulation and Research Food and Drug Administration 17 December
More informationROLES, RESPONSIBILITIES AND DELEGATION OF DUTIES IN CLINICAL TRIALS OF MEDICINAL PRODUCTS
ROLES, RESPONSIBILITIES AND DELEGATION OF DUTIES IN CLINICAL TRIALS OF MEDICINAL PRODUCTS STANDARD OPERATING PROCEDURE NO SOP 09 DATE RATIFIED 4/7/13 NEXT REVIEW DATE 4/7/14 POLICY STATEMENT/KEY OBJECTIVES:
More informationStandard Operating Procedures (SOP) for: Reporting of Serious Breaches of GCP or the Trial Protocol sponsored CTIMP s. Lisa Austin, Research Manager
Standard Operating Procedures (SOP) for: Reporting of Serious Breaches of GCP or the Trial Protocol sponsored CTIMP s Author: Lisa Austin, Research Manager Purpose and Objective: To identify and standardise
More informationGCP - Records Managers Association
GCP - Records Managers Association Guidance on the Scanning and Destruction of Paper Records 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 The introduction
More informationStandard Operating Procedure on Training Requirements for staff participating in CTIMPs Sponsored by UCL
Page 1 of 10 Standard Operating Procedure on Training Requirements for staff participating in CTIMPs Sponsored by UCL SOP ID Number: Effective Date:01/08/2012 Version Number & Date of Authorisation: V02,
More informationAuditing as a Component of a Pharmaceutical Quality System
Auditing as a Component of a Pharmaceutical Quality System Tim Fields Conducting internal audits (or self inspections) and external audits of suppliers and outsourcing operations are key elements of a
More informationDocument Title: Project Management of Papworth Sponsored Studies
Document Title: Project Management of Papworth Sponsored Studies Document Number: SOP009 Staff involved in development: Job titles only Document author/owner: Directorate: Department: For use by: RM&G
More informationGuidance notes on the management of adverse events and product complaints from digital media
Guidance notes on the management of adverse events and product complaints from digital media Guidance notes on the management of adverse events and product complaints from digital media ABPI Pharmacovigilance
More informationEDQM Certificates of Suitability: Cooperation Among Inspectorates in Europe And Beyond
EDQM Certificates of Suitability: Cooperation Among Inspectorates in Europe And Beyond 14 th International Conference of Drug Regulatory Authorities Pre-ICDRA Meeting Dr Susanne Keitel European Directorate
More informationEU PAS Register Guide
29 March 2016 EMA/613603/2012 (currently ENCePP E-Register of Studies) The EU PAS Register is temporarily hosted on the ENCePP website www.encepp.eu 1. Introduction... 2 2. ENCePP E-Register as a temporary
More informationGuideline on good pharmacovigilance practices (GVP)
9 April 2013 EMA/816573/2011 Rev 1* Guideline on good pharmacovigilance practices (GVP) Module II Pharmacovigilance system master file (Rev 1) Draft of first version finalised by the Agency in collaboration
More informationASSESSMENT OF QUALITY RISK MANAGEMENT IMPLEMENTATION
PHARMACEUTICAL INSPECTION CONVENTION PHARMACEUTICAL INSPECTION CO-OPERATION SCHEME PI 038-1 26 March 2012 AIDE-MEMOIRE ASSESSMENT OF QUALITY RISK MANAGEMENT IMPLEMENTATION PIC/S March 2012 Reproduction
More informationRisk Management Primer
Risk Management Primer Purpose: To obtain strong project outcomes by implementing an appropriate risk management process Audience: Project managers, project sponsors, team members and other key stakeholders
More informationOptimizing Quality Control / Quality Assurance Agents of a Global Sourcing / Procurement Strategy
Optimizing Quality Control / Quality Assurance Agents of a Global Sourcing / Procurement Strategy Global Pharma Sourcing Conference December 6-7, 2011 Philadelphia, USA Nigel J. Smart, Ph.D. Smart Consulting
More informationgsop-32-02 - Vendor Assessment SOP page 1 of 10
gsop-32-02 - Vendor Assessment SOP page 1 of 10 Hertfordshire Hospitals R&D Consortium Incorporating West Herts Hospitals NHS Trust and East & North Herts NHS Trust VENDOR ASSESSMENT Research & Development
More informationOverview of Risk Management
Overview of Risk Management Risk Management Plans- An Industry Perspective Dr. Sudhichai Chokekijchai, CSO Novartis (Thailand) Limited (adapted from an RMP training by Dr Judith Sills, Global Head, Medical
More informationEFPIA Principles for the Development of the EU Clinical Trials Portal and Database
Position Paper EFPIA Principles for the Development of the EU Clinical Trials Portal and Database Executive summary EFPIA sees the implementation of the Clinical Trials Regulation 1 as an opportunity to
More informationGuideline on good pharmacovigilance practices (GVP)
1 2 20 February 2012 EMA/541760/2011 3 4 Guideline on good pharmacovigilance practices (GVP) Module I Pharmacovigilance systems and their quality systems Draft finalised by the Agency in collaboration
More informationEdwin Lindsay Principal Consultant. Compliance Solutions (Life Sciences) Ltd, Tel: + 44 (0) 7917134922 E-Mail: elindsay@blueyonder.co.
Edwin Lindsay Principal Consultant, Tel: + 44 (0) 7917134922 E-Mail: elindsay@blueyonder.co.uk Corrective and Preventative Action (CAPA) is a system of quality procedures required to eliminate the causes
More informationQuality in pharmacovigilance systems
Quality in pharmacovigilance systems June 20 th, 2014 Lisa Stagi, Medical Compliance Leader Roche Spa Quality systems in pharmacovigilance: legal requirements Regulation 1235/2010 e Directive 2010/84 Legal
More informationHealth Canada s GCP Compliance Program Part 2. GCP Information Sessions November 2010
Your Health and Safety... Our priority Votre santé et votre Securité notre priorité Health Canada s GCP Compliance Program Part 2 GCP Information Sessions November 2010 Inspection Program Main objectives
More informationDocument Title: Trust Approval and Research Governance
Document Title: Trust Approval and Research Governance Document Number: SOP034 Staff involved in development: Job titles only Document author/owner: Directorate: Department: For use by: RM&G Manager, R&D
More informationMRP & DCP step by steb instructions how to apply and how the procedures are conducted
MRP & DCP step by steb instructions how to apply and how the procedures are conducted 06 May 2013 Dubrovnik, Croatia Dr. Peter Bachmann Head of Unit Coordination Group European and International Affairs
More informationEUROPEAN INDUSTRIAL PHARMACISTS GROUP
EUROPEAN INDUSTRIAL PHARMACISTS GROUP Guide to Good Regulatory Practice Acknowledgments: Valérie LACAMOIRE, Conseil Central de la section B de l Ordre des Pharmaciens Kelsey MOWER, Industrial Pharmacists
More informationNRA FUNCTION IN CONTROLLING VACCINES IN CLINICAL TRIAL AND MARKETING AUTHORIZATION INDONESIA 2013 DVI MEETING 9 11 APRIL 2013 1
NRA FUNCTION IN CONTROLLING VACCINES IN CLINICAL TRIAL AND MARKETING AUTHORIZATION INDONESIA 2013 DVI MEETING 9 11 APRIL 2013 1 2 The National Agency of Drug and Food Control (NA-DFC) is a non departmental
More informationWhat is necessary to provide good clinical data for a clinical trial?
What is necessary to provide good clinical data for a clinical trial? Alain Barrois, Assistant Clinical Trials Operations Manager #EBMT2015 www.ebmt.org Is this a (typical) clinical trial? 2 Agenda Introduction
More informationAdoption by GCP Inspectors Working Group for consultation 14 June 2011. End of consultation (deadline for comments) 15 February 2012
10 December 2013 EMA/INS/GCP/600788/2011 Compliance and Inspection Reflection paper on the use of interactive response technologies (interactive voice/web response systems) in clinical trials, with particular
More informationHealth Canada s GCP Compliance Program. GCP Information Sessions November 2010
Your Health and Safety... Our priority Votre santé et votre Securité notre priorité Health Canada s GCP Compliance Program GCP Information Sessions November 2010 Objective To describe the role that Health
More informationBest Practice In A Change Management System
Quality & Compliance Associates, LLC Best Practice In A Change Management System President Quality & Compliance Associates, LLC Change Control and Its Role in a Continuous Improvement Environment 3 Benefits
More informationMedicines and Healthcare products Regulatory Agency
Medicines and Healthcare products Regulatory Agency 11 April 2016 Update on progress with the Joint Patient Safety and Vigilance Strategy Purpose: This paper provides the Board with an update on the Joint
More informationDistant/virtual pharmacovigilance inspections of MAHs during a crisis situation- Points to consider
18 January 2013 EMA/INS/119905/2012 Compliance and Inspection Distant/virtual pharmacovigilance inspections of MAHs during a crisis situation- Points This document is intended to provide guidance on the
More informationEUROPEAN MEDICINES PRACTICES AND TOOLS AGENCY DRUG SAFETY
EUROPEAN MEDICINES AGENCY DRUG SAFETY PRACTICES AND TOOLS Henry Fitt, Kevin Blake, Xavier Kurz Pharmacovigilance & Risk Management European Medicines Agency, London Contents Eudravigilance & Signal Detection
More informationFrom paper to electronic data
From paper to electronic data Bioindustrypark, October 10, 2013 Dr Alessandra Grande Ivrea GxP Test Facility QA Manager, Head Global BMT QA Research & Development Quality Assurance MerckSerono RBM Outline
More informationEMEA RM DRAFT GUIDANCE ISPE RESPONSE 1
EMEA RM DRAFT GUIDANCE ISPE RESPONSE 1 October 4, 2005 Guideline on Risk Management Systems for Medicinal Products for Human Use DRAFT London, 6 September 2005. This guideline will be included as chapter
More informationQuality Risk Management The Pharmaceutical Experience Ann O Mahony Quality Assurance Specialist Pfizer Biotech Grange Castle
Quality Risk Management 11 November 2011 Galway, Ireland Quality Risk Management The Pharmaceutical Experience Ann O Mahony Quality Assurance Specialist Pfizer Biotech Grange Castle Overview Regulatory
More information(Article 131(2) of the Financial Rules of the Innovative Medicines Initiative Joint Undertaking)
Annual report of the Executive Director to the Discharge on measures taken in the light of the Discharge s recommendations of 2012 in respect of the implementation of the budget of 2010 (Article 131(2)
More informationThe European regulatory system for medicines and the European Medicines Agency
The European regulatory system for medicines and the European Medicines Agency A consistent approach to medicines regulation across the European Union An agency of the European Union This booklet is intended
More informationICH Q10 - Pharmaceutical Quality System
WCC PDA Dinner Meeting Jan 2012 ICH Q10 - Pharmaceutical Quality System Neil Wilkinson NSF-DBA www.nsf-dba.com ICHQ10.1 WCC PDA Dinner Meeting Jan 2012 Your Presenter Partner at NSF-DBA USA Training, Consultancy,
More informationReflection Paper on Medicinal Product Supply Shortages Caused by Manufacturing/GMP Compliance Problems
14 September 2012 /590745/2012 Patient Health Protection Reflection Paper on Medicinal Product Supply Shortages Caused by Manufacturing/GMP 1. Introduction Ensuring the security and Good Manufacturing
More informationRisk Management Plan (RMP) Guidance (Draft)
Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare Translated by Pharmaceuticals and Medical Devices Agency Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour
More informationQuestions & answers on signal management
23 October 2015 EMA/261758/2013 Inspections and Human Medicines Pharmacovigilance Division This document addresses a number of questions which stakeholders, in particular marketing authorisation holders
More informationReport to the European Commission on Pharmacovigilance audits carried out in the Medicines Evaluation Board, The Netherlands period of time from
Report to the European Commission on Pharmacovigilance audits carried out in the Medicines Evaluation Board, The Netherlands period of time from September 2013 to September 2015 1. INTRODUCTION Applicable
More informationCOMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINE FOR THE CONDUCT OF POST-MARKETING SURVEILLANCE STUDIES OF VETERINARY MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Information Technology EMEA/CVMP/044/99-FINAL COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINE FOR THE CONDUCT
More informationQuality Agreements: Contractual Commitments by CROs to Deliver High-Quality Work
Vol. 10, No. 11, November 2014 Happy Trials to You Quality Agreements: Contractual Commitments by CROs to Deliver High-Quality Work By Tom McGrady and Susan Callery-D Amico Introduction Regulated companies
More informationValidation Consultant
Personal Data Name Title Validation Consultant Contact jsb-validierung Zwischen den Bächen 9 D 79618 Rheinfelden Tel: +49 7623 79 49 82 Mobile: +49 172 737 84 86 E-Mail: Internet: jsb-val@online.de http://www.jsb-validierung.de
More informationR&D Administration Manager. Research and Development. Research and Development
Document Title: Document Number: Patient Recruitment SOP031 Staff involved in development: Job titles only Document author/owner: Directorate: Department: For use by: RM&G Manager, R&D Administration Manager,
More informationEstablishment of a Quality Systems approach to Clinical Site Management An Overview of Standard Operating Procedures (SOPs)
Establishment of a Quality Systems approach to Clinical Site Management An Overview of Standard Operating Procedures (SOPs) Cornelia Kamp, MBA Executive Director Strategic Initiatives Tim Hackett Director
More informationCompliance Focused Preapproval Preparation Program. By Mike Ronningen, RAC
Compliance Focused Preapproval Preparation Program By Mike Ronningen, RAC 14 July 2011 Submitting a Premarket Approval Application (PMA) for a Class III medical device to the US Food and Drug Administration
More informationAssociate Group Director, Regulatory Intelligence & Policy
Date: 06/24/16 Associate Group Director, Regulatory Intelligence & Policy Job ID: 2974410847 Job Function Project Management Regulatory Affairs Location United States - District of Columbia Washington
More informationZ.A.S. Archive- and informationsmanagement
Z.A.S. Archive- and informationsmanagement Presentation at SAG Scientific Archivists Group Spring Conference in Basel 11 June 2010 Electronic Archiving in a GXP-regulated environment Author: Bernd Mohnsame
More information20 & 21 October 2005 Clinical trials Risk issues within a wider Europe. Adrien Collovray Marsh Life Science Conference 2005 Berlin, Germany
20 & 21 October 2005 Clinical trials Risk issues within a wider Europe Adrien Collovray Life Science Conference 2005 Berlin, Germany Clinical trials EC Directive on clinical trials Insurance Requirements
More informationAdventist HealthCare, Inc.
IRB POLICY ON HUMAN RESEARCH PROTECTION (HRP) AND GOOD CLINICAL PRACTICE (GCP) TRAINING Collaborative Institutional Training Initiative (CITI) Requirements at Adventist Healthcare, Inc. I. Required Human
More informationHow companies leverage quality and quality certifications to achieve competitive advantage
How companies leverage quality and quality certifications to achieve competitive advantage Eize de Boer Systems & Services Certification International Business Development Manager Pharma Supply Chain for
More informationICH guideline Q10 on pharmaceutical quality system
September 2015 EMA/CHMP/ICH/214732/2007 Committee for Human Medicinal Products Step 5 Transmission to CHMP May 2007 Transmission to interested parties May 2007 Deadline for comments November 2007 Final
More informationDetailed guidance AEs reporting in clinical trials ( CT-3 ) Stefano Bonato, M.D. Pharmacovigilance Country Head Bayer HealthCare Pharmaceuticals
Detailed guidance AEs reporting in clinical trials ( CT-3 ) Stefano Bonato, M.D. Pharmacovigilance Country Head Bayer HealthCare Pharmaceuticals Pharmacovigilance costs 0.12%-0.22% of hospital admissions
More informationGuideline on good pharmacovigilance practices (GVP)
22 June 2012 EMA/541760/2011 Guideline on good pharmacovigilance practices (GVP) Module I Pharmacovigilance systems and their quality systems Draft finalised by the Agency in collaboration with Member
More informationRole of IRB/IEC in GCP. Benjamin Kuo, MD, Dr.PH, CIP.
Role of IRB/IEC in GCP Benjamin Kuo, MD, Dr.PH, CIP. Institutional Review Board (IRB) An independent body constituted of medical, scientific and non scientific members Responsible for ensuring protection
More informationHealthcare Governance Alert and Guidance Review Procedure
Healthcare Governance Alert and Guidance Review Procedure Healthcare Governance Alert and Guidance Review Procedure Page: Page 1 of 20 Recommended by Approved by Quality Directorate/Medical Directorate
More informationObjectives. Project Management Overview. Successful Project Fundamentals. Additional Training Resources
Project Management for Small Business Moderator: Maria Mancha Frontline Systems, Inc. Objectives Project Management Overview Successful Project Fundamentals Additional Training Resources Project Management
More informationA Guide to Pharmacy Documentation For Clinical Trials
A Guide to Pharmacy Documentation For Clinical Trials Roy Sinclair Clinical Trials Pharmacist St. George s Hospital (to Sep 2007) Lecturer Kingston University January 2008 A Guide to Pharmacy Documentation
More informationEuropean Forum for Good Clinical Practice Audit Working Party
European Forum for Good Clinical Practice Audit Working Party REVISION OF THE ENGAGE 1 AUDITING GUIDELINE. AN OPTIONAL GUIDELINE FOR GCP COMPLIANCE AND QUALITY MANAGEMENT SYSTEMS AUDITING This document
More informationAchieve. Performance objectives
Achieve Performance objectives Performance objectives are benchmarks of effective performance that describe the types of work activities students and affiliates will be involved in as trainee accountants.
More informationWelcome to the training on the TransCelerate approach to Risk-Based Monitoring. This course will take you through five modules of information to
Welcome to the training on the TransCelerate approach to Risk-Based Monitoring. This course will take you through five modules of information to introduce you to the concepts behind risk-based monitoring,
More informationTSM ASSESSMENT PROTOCOL
TSM ASSESSMENT PROTOCOL A Tool for Assessing Crisis Management and Communications Planning Performance Purpose The purpose of the assessment protocol is to provide guidance to the member companies in completing
More informationGMP Training Course Quality Control. 20-21 October 2009. Lesley Graham Senior Inspector (UK)
GMP Training Course Quality Control 20-21 October 2009 Lesley Graham Senior Inspector (UK) Quality Control GMP in the QC Laboratory Certificates of Analysis Dealing with out of specification results Parametric
More information